Growth Hormone Secretagogue (GHS)

A growth hormone secretagogue (GHS) is any compound that triggers the pituitary gland to release more of its own growth hormone, rather than supplying growth hormone directly. In peptide research, GHS is the umbrella category that ties together several distinct compound families, growth hormone-releasing hormone (GHRH) analogs and ghrelin-mimetic growth hormone-releasing peptides (GHRPs), which work through different receptors but converge on the same downstream effect: a pulse of endogenous GH secretion. Knowing a compound is a GHS tells you it's working with the body's own pituitary signaling rather than bypassing it, which is the key distinction researchers use to sort this entire category of peptides from synthetic HGH itself. It's also a different mechanism entirely from bioregulator peptides, which act on gene expression rather than a specific receptor, or nootropic peptides, which target cognition rather than growth hormone pathways.

Within the GHS category, the two main mechanisms are worth separating because they're often stacked together in research protocols specifically because they're complementary, not redundant. GHRH analogs, compounds like CJC-1295 and Sermorelin, bind the GHRH receptor and increase the amplitude of a natural GH pulse. GHRPs, compounds like Ipamorelin, bind the ghrelin receptor instead, and increase both the frequency and amplitude of pulses through a separate signaling pathway. Because the two mechanisms act on different receptors, combining a GHRH analog with a GHRP produces a synergistic effect beyond what either produces alone, which is why so much of the published research and so many protocol designs pair one from each category rather than using either alone.

The practical reason "GHS" matters as a category, rather than just learning each compound individually, is that it predicts a compound's general behavior before you've read its specific profile: any GHS-class peptide will depend on a functioning pituitary gland to work at all (unlike direct HGH, which doesn't), will produce a pulsatile release pattern rather than a flat elevation, and will be subject to natural feedback regulation that puts a ceiling on how much GH release it can trigger, even at higher doses. That's a fundamentally different risk and mechanism profile than administering HGH directly, and it's why GHS compounds get discussed and dosed differently in the literature. GHS peptides sold for research are also typically labeled Research Use Only (RUO), with purity verified through a certificate of analysis built on HPLC-MS testing rather than through FDA-regulated pharmaceutical review.

Ipamorelin, CJC-1295, Tesamorelin, and Sermorelin are the four GHS compounds most commonly referenced in peptide research protocols, and each has its own dedicated profile covering mechanism, half-life, and how it's typically studied. Tesamorelin in particular stands apart from the other three in that it's the only one with FDA approval, specifically for HIV-associated lipodystrophy, which makes it the most clinically documented member of the category even though it shares the same GHRH-analog mechanism as CJC-1295 and Sermorelin. Understanding GHS as a category is what makes those four individual profiles make sense together rather than as four unrelated compounds: they're variations on a shared mechanism, not a random list.

Half-life is another axis where the category splits meaningfully. Sermorelin has a very short half-life, on the order of minutes, so its research protocols typically involve more frequent administration to sustain a pulsatile effect. CJC-1295 is often studied in a modified form bound to Drug Affinity Complex (DAC), which extends its half-life to several days and produces a sustained elevation in GH pulse amplitude rather than a single discrete pulse, a meaningfully different pharmacokinetic profile from the unmodified GHRH analogs it's otherwise mechanistically similar to. Ipamorelin, by contrast, is valued in the GHRP subclass specifically for its selectivity: unlike older ghrelin-receptor agonists, it doesn't meaningfully stimulate cortisol or prolactin alongside GH, which is why it's the GHRP most frequently paired with a GHRH analog in stacked protocols rather than used alone.